3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Ovarian Neoplasms
8
Fallopian Tube Neoplasms
7
Breast Neoplasms
6
Neoplasms
5
Triple Negative Breast Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Endometrial Neoplasms
4
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate
1
Pheochromocytoma
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Paraganglioma
1
Interventions
durvalumab
2
Tretinoin
2
Paclitaxel
2
Carboplatin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
STA 9090
1
SGN-LIV1A
1
Pemetrexed
1
MK 2206
1
Letrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
olaparib
×
30 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled